Syros Pharmaceuticals (NASDAQ:SYRS)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a research note issued to investors on Tuesday, MarketBeat.com reports. They presently have a $13.00 price objective on the stock, up from their prior price objective of $11.00. Wedbush’s price objective would indicate a potential upside of 6.21% from the company’s previous close.
A number of other equities analysts have also recently weighed in on the stock. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Oppenheimer reiterated a “buy” rating and set a $28.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 7th. HC Wainwright reiterated a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, December 21st. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 target price on the stock. in a report on Saturday, January 20th. Finally, BidaskClub upgraded shares of Syros Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. Syros Pharmaceuticals has an average rating of “Hold” and an average target price of $21.13.
Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.49 during trading hours on Tuesday, hitting $12.24. 67,153 shares of the company were exchanged, compared to its average volume of 259,829. The stock has a market cap of $401.46, a PE ratio of -5.95 and a beta of -2.26. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.38.
In related news, insider Jeremy P. Springhorn bought 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average cost of $9.08 per share, with a total value of $136,200.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Srinivas Akkaraju bought 209,424 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was bought at an average cost of $9.55 per share, for a total transaction of $1,999,999.20. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of SYRS. ARK Investment Management LLC grew its position in shares of Syros Pharmaceuticals by 519.7% in the 4th quarter. ARK Investment Management LLC now owns 834,757 shares of the company’s stock valued at $8,122,000 after buying an additional 700,058 shares during the last quarter. Vanguard Group Inc. grew its position in Syros Pharmaceuticals by 189.6% during the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock worth $6,156,000 after purchasing an additional 250,507 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new position in Syros Pharmaceuticals during the 3rd quarter worth $1,766,000. State Street Corp grew its position in Syros Pharmaceuticals by 176.7% during the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock worth $2,728,000 after purchasing an additional 108,250 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in Syros Pharmaceuticals during the 3rd quarter worth $975,000. 48.18% of the stock is currently owned by hedge funds and other institutional investors.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.